Brookdale Senior Living (BKD) Stephens 26th Annual Investment Conference | NASH2024 summary
Event summary combining transcript, slides, and related documents.
Stephens 26th Annual Investment Conference | NASH2024 summary
13 Jan, 2026State of the business and recent actions
Consistent occupancy and RevPAR growth are driving improved cash flow and recovery from the pandemic.
Recent acquisitions of leased portfolios provide flexibility and attractive returns.
Demographic tailwinds and constrained supply are expected to propel future growth.
Advocacy efforts focus on affordability and healthcare worker availability, including potential policy changes for FSAs/HSAs.
Studies show residents in senior living have better health outcomes and lower healthcare utilization.
Strategic planning and financial outlook
2024 saw 15% adjusted EBITDA growth and 31% adjusted free cash flow growth through Q3.
2025 is expected to continue this growth, with a focus on sustainable RevPAR and occupancy.
Headwinds include insurance and health costs; tailwinds include demographic trends and improved associate retention.
Interest rate changes have a significant impact, with 1% change equating to $13 million on variable debt.
Majority of debt is fixed or hedged, with recent refinancing lowering average rates.
Workforce and retention
Key leadership retention rates are around 70%, with hourly turnover better than comparable industries.
Nurse turnover remains a challenge due to industry-wide shortages.
Focus on onboarding, development, and hiring for cultural fit to improve retention.
Advancement programs and support for citizenship applications help attract and retain talent.
Latest events from Brookdale Senior Living
- Operational focus, targeted CapEx, and market-driven M&A support growth amid strong demand.BKD
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Record 2025 EBITDA and occupancy set stage for robust 2026 growth and portfolio streamlining.BKD
Q4 202519 Feb 2026 - Q2 saw 20% Adjusted EBITDA growth, higher occupancy, but a wider net loss on higher costs.BKD
Q2 20241 Feb 2026 - 2026 targets $502–$516M Adjusted EBITDA and 8–9% RevPAR growth, led by operational transformation.BKD
Investor Day 202630 Jan 2026 - Q3 2024 delivered 15% EBITDA growth, higher occupancy, and $610M in acquisitions pending.BKD
Q3 202415 Jan 2026 - Accelerating occupancy, strong cash flow, and innovation position for sustained growth.BKD
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - 2024 results beat guidance; 2025 targets 11%-15% EBITDA growth and positive cash flow.BKD
Q4 202415 Dec 2025 - Contested director election, performance-based pay, and auditor ratification headline the 2025 proxy.BKD
Proxy Filing1 Dec 2025 - Ortelius seeks to overhaul board leadership to address underperformance and drive value creation.BKD
Proxy Filing1 Dec 2025